CompletedNCT00218231
Bupropion compared with placebo for smoking behavior in schizophrenia
About this title
Read the official source — NCT00218231Medication studyAges 18–80United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 80 years.
- Listed locations
- Providence and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateJanuary 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 48
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 80 Years
- Official registry ID
- NCT00218231
- Official title
Show the full official title
Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Providence
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.
Did this study involve medication?
Yes. The study involved medication, including 300 mg/day bupropion-sr and 0 mg/day bupropion-sr.
Who was this study for?
Listed age limits: 18 years to 80 years.
